Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)star, open

[tetano]

Vaccine
doi:10.1016/j.vaccine.2010.10.079 | How to Cite or Link Using DOI
Copyright ? 2010 Published by Elsevier Ltd.
Permissions & Reprints
Conference report
Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)star, open
Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Germaine Hanquetc, Pierre van Dammed, Daniel Brasseure, Xavier de Cuypere, Simon Gregorf, Martin Holmbergg, Rebecca Martinh, Zsuzsanna Molnari, Maria Grazia Pompaj, Ren? Snackenk, Marianne van der Sandea, b, Marc Van Ranstl, Angela Wirzm and Pieter Neels



Abstract

This European workshop identified a number of lessons learnt in the field of vaccine licensure, prioritisation of target groups, communication on pandemic vaccines, implementation of vaccination and safety monitoring. The mild severity of the pandemic A(H1N1) 2009 influenza virus influenced the perception of pandemic vaccines, as previous pandemic preparedness had anticipated a more virulent virus. This vaccination experience provides an important opportunity for research on the long-term immunogenicity and safety of pandemic vaccines in pregnant women and children, as well as on the long-term safety of adjuvants. Preparedness for future pandemics could involve improved decision-making on target groups and increased communication on vaccine safety.


http://www.sciencedirect.com/scienc...b5060b7c53f425bb3dd6fe3920352bb3&searchtype=a

 

[tetano]

Re: Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)star, open

Europe sees need for better pandemic communication, vaccine data
Although European countries had different strategies for addressing pandemic 2009 H1N1 influenza, they faced similar problems and have learned universal lessons, such as the need for sound data on vaccine safety and efficacy to counteract misconceptions. The retrospective report found that similar age-groups were most affected across Europe: children younger than 14, followed by young adults. It also found low levels of vaccine uptake, with the exception of the Netherlands, which saw uptake of 76% in risk groups and 74% in children. The low uptake was in part attributed to anti-vaccine sentiment, including suspicion of new adjuvants. The report recommends (1) improving communication on vaccine issues; (2) standardizing vaccine priority groups; (3) obtaining sound data on vaccine efficacy and safety in pregnant women and in children, as well as on the long-term effects of adjuvants; (4) determining whether single-dose vials would work best; and (5) coordinating vaccine licensing policies with declared pandemic phases.

http://www.cidrap.umn.edu//cidrap/content/bt/bioprep/news/nov1510newsscan.html